Clinical Updates and New Approaches: Prostate Cancer, Lung Cancer, and Clinical Support & Outcomes

Last Modified: November 14, 2003

Program Description and Objectives

As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to maintain an awareness and understanding of the vast array of therapeutic choices that is available is, at the very least, "daunting". The ASCO 2003 meeting featured over 3,600 abstracts covering preclinical and clinical developments for currently commercialized agents, as well as new agents not yet approved, across all tumor-types. The number of anticancer agents in clinical trials is estimated to exceed 400. There are limited opportunities for clinicians to hear key opinion leaders, specializing in all major oncology specialties, present cutting edge clinical information. Professional forums, such as ASCO and the Chemotherapy Foundation, provide rare opportunities for oncology professionals to hear, first-hand from investigators, the latest data and interpretation for cancer treatments spanning all major tumor-types.

The Chemotherapy Foundation Symposium (CFS) provides "coverage of emerging advances in the treatment of neoplastic diseases" and affords the opportunity "to learn about the new drugs, new modalities, current trials, new procedures and evolving developments in biotherapies". OncoLink will report on key presentations to enhance the learning opportunities of the oncology professional. This module will report on clinical updates and new approaches under investigation for the treatment of prostate cancer and lung cancer, plus clinical support and outcomes.

After completing this program, participants will be able to:

  • Define how new therapeutic advances in prostate and lung cancer may be incorporated into patient care.
  • Identify new concepts in the treatment of prostate and lung cancers.
  • Describe new approaches under investigation that employ targeted therapies for prostate and lung cancers.
  • Discuss recent clinical trials and their clinical implications for agents used in clinical support and outcomes implications.


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The American Academy of CME, Inc., is accredited by the ACCME to provide continuing medical education for physicians.


The American Academy of CME, Inc., designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Term of Approval

This educational activity has been approved through November 2004.

Faculty Disclosures

  • Joel Picus, M.D.
    Nothing to Disclose
  • James L. Mulshine, M.D.
    Nothing to Disclose
  • Gerold Bepler, M.D., Ph.D.
    NCI - Research Support, Consultant
    Lilly - Research Support
  • Hak Choy, M.D.
    Aventis - Research Support, Speakers Bureau
  • Howard A. Burris, II, M.D.
    Cell Therapeutics - Research Support, Consultant, Speakers Bureau
    Aventis - Research Support, Consultant, Speakers Bureau
    BMS - Research Support, Consultant, Speakers Bureau
    Genentech - Research Support, Consultant, Speakers Bureau
    Amgen - Research Support, Speakers Bureau
    Lilly - Research Support, Speakers Bureau
    Celgene - Research Support, Consultant, Speakers Bureau
  • Chandra P. Belani, M.D.
    BMS - Research Support, Consultant
    Aventis - Research Support, Consultant
    Lilly - Research Support, Consultant
    AstraZeneca - Research Support, Consultant
  • Roy S. Herbst, M.D., Ph.D.
  • Corey J. Langer, M.D.
    Ortho Biotech - Research Support, Consultant, Speakers Bureau
    Amgen - Research Support, Consultant, Speakers Bureau
  • Roger J. Waltzman, M.D.
    Nothing to Disclose
  • Michael Green, M.D.
    Nothing to Disclose
  • Michael J. Keating, M.B., B.S.
    Berlex - Research Support, Consultant, Speakers Bureau
    Genentech - Research Support, Speakers Bureau

Instructions for Applying for CME

After reading all of the articles within this module you will be able to download the Program Evaluation (a PDF file), which you can print out. In order to receive your CME certificate, please complete the form and mail or fax as shown on the form.

Certificates will be mailed 6 to 8 weeks following receipt of your evaluation.

Prostate Cancer

Bevacizumab (Avastin) In Advanced Prostate Cancer

Joel Picus, M.D.

Lung Cancer

Tumor Markers And Early Detection

James L. Mulshine, M.D.

Molecular Prediction Of Response And Survival In NSCLC

Gerold Bepler, M.D., Ph.D.

Novel Approaches In Stage III NSCLC

Hak Choy, M.D.

CT-2103 (Xyotax): Phase II Trial Of A Polyglutamated Paclitaxel Conjugate In Advanced NSCLC

Howard A. Burris, II, M.D.

Optimized Schedule Of Wkly Paclitaxel Alone And With Carboplatin: Elderly Advanced NSCLC Patients

Chandra P. Belani, M.D.

Erlotinib (Tarceva) And Bevacizumab (Avastin): Combination Therapy For NSCLC

Roy S. Herbst, M.D., Ph.D.

Clinical Support And Outcomes

Impact And Therapeutic Implications Of Anemia In Lung Cancer

Corey J. Langer, M.D.

Erythropoietic Agents: Recent Clinical Data

Roger J. Waltzman, M.D.

Neutropenia Control: Optimizing Therapeutic Gains

Michael Green, M.D.

Michael J. Keating, M.B., B.S.



Click on any of these terms for more related articles


I wish u knew... Caring for people with advanced lung cancer
by Timothy J. Hampshire
January 07, 2013

Cancer Center Advertising: Doing More Harm Than Good?
by Rodney Warner, JD
July 21, 2016